AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has earned a consensus rating of “Buy” from the seven brokerages that are presently covering the firm. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $9.80.

Several analysts have recently weighed in on ACRX shares. Roth Capital set a $15.00 price target on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, March 6th. Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price objective for the company in a research report on Wednesday, May 3rd. Stifel Nicolaus lowered their price objective on shares of AcelRx Pharmaceuticals from $15.00 to $14.00 and set a “hold” rating for the company in a research report on Tuesday, March 14th. Cowen and Company reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Monday, March 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $6.00 price objective on shares of AcelRx Pharmaceuticals in a research report on Friday, March 3rd.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new position in shares of AcelRx Pharmaceuticals during the fourth quarter worth about $14,063,000. Oxford Asset Management boosted its position in shares of AcelRx Pharmaceuticals by 48.7% in the fourth quarter. Oxford Asset Management now owns 103,420 shares of the specialty pharmaceutical company’s stock worth $269,000 after buying an additional 33,866 shares during the last quarter. Acadian Asset Management LLC boosted its position in AcelRx Pharmaceuticals by 326.1% in the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 32,087 shares in the last quarter. ING Groep NV boosted its position in AcelRx Pharmaceuticals by 200.0% in the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 26,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in AcelRx Pharmaceuticals by 1.5% in the first quarter. Vanguard Group Inc. now owns 1,539,535 shares of the specialty pharmaceutical company’s stock worth $4,849,000 after buying an additional 22,961 shares in the last quarter. 35.01% of the stock is owned by institutional investors.

AcelRx Pharmaceuticals (NASDAQ:ACRX) remained flat at $2.55 on Friday. The stock had a trading volume of 147,879 shares. The firm’s market cap is $115.72 million. AcelRx Pharmaceuticals has a 1-year low of $2.25 and a 1-year high of $4.08. The firm has a 50-day moving average of $2.62 and a 200-day moving average of $2.87.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its quarterly earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.06. AcelRx Pharmaceuticals had a negative net margin of 347.94% and a negative return on equity of 232.39%. The firm had revenue of $3.11 million during the quarter, compared to analysts’ expectations of $2.36 million. Equities analysts forecast that AcelRx Pharmaceuticals will post ($1.10) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/05/29/acelrx-pharmaceuticals-inc-acrx-given-average-recommendation-of-buy-by-brokerages-2-updated.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.